Diffusion Pharmaceuticals Inc. (DFFN): Price and Financial Metrics

Diffusion Pharmaceuticals Inc. (DFFN)

Today's Latest Price: $0.95 USD

0.00 (0.34%)

Updated Jul 2 4:00pm

Add DFFN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

DFFN Daily Price Range
DFFN 52-Week Price Range

DFFN Stock Price Chart Technical Analysis Charts

DFFN Price/Volume Stats

Current price $0.95 52-week high $2.72
Prev. close $0.95 52-week low $0.21
Day low $0.91 Volume 1,159,154
Day high $0.96 Avg. volume 5,383,617
50-day MA $0.93 Dividend yield N/A
200-day MA $0.74 Market Cap 45.95M

Diffusion Pharmaceuticals Inc. (DFFN) Company Bio

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. The company is based in Charlottesville, Virginia.

DFFN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

DFFN Latest Social Stream

Loading social stream, please wait...

View Full DFFN Social Stream

Latest DFFN News From Around the Web

Below are the latest news stories about Diffusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate DFFN as an investment opportunity.

Diffusion Pharma to initiate early-stage TSC study in COVID-19 patients in Europe

Diffusion Pharmaceuticals ([[DFFN]] -9.3%) submits Clinical Trial Application to the Romanian National Agency for Medicines and Medical Devices ((NAMMD)) to initiate a Phase 1a/1b clinical trial of the Company's oxygenation-enhancing product candidate trans sodium crocetinate ((TSC)) for the treatment of hospitalized COVID-19 patients displaying severe respiratory symptoms and low oxygen levels. Diffusion...

Seeking Alpha | June 11, 2020

Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients

Low oxygen levels occur as a consequence of damage to the lungs from COVID-19 and often result in mechanical ventilation and, if that is ineffective, multiple organ failure – the leading cause of death in COVID-19 patients. Assuming NAMMD authorization of the CTA and approval by the National ethics committee under NAMMD’s accelerated seven-working-day approval process, Diffusion plans to begin the 24 patient Phase 1a portion of the clinical trial by the end of Q2 2020.

Yahoo | June 11, 2020

Diffusion Pharmaceuticals regains Nasdaq compliance

Diffusion Pharmaceuticals (DFFN) has regained compliance with the Nasdaq minimum bid price requirement for continued listing.DFFN -2.4% premarket....

Seeking Alpha | June 2, 2020

Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

The Company had previously been notified by Nasdaq on December 11, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. In order to regain compliance with Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on May 28, 2020. The Company’s last closing bid price on May 28 was $1.27.

Yahoo | June 1, 2020

Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program

The PIND was filed on April 27, seeking FDA guidance on the Company’s proposed clinical development program for the use of trans sodium crocetinate (TSC) in COVID-19 patients displaying severe respiratory symptoms and low oxygen levels. The FDA’s accelerated response to the PIND meeting request recommended that the first U.S. TSC COVID-19 study employ a double-blinded, controlled, randomized clinical trial design to address the wide variability in standard of care due to the rapidly evolving COVID-19 experience.

Yahoo | May 26, 2020

Read More 'DFFN' Stories Here

DFFN Price Returns

1-mo -10.38%
3-mo 120.88%
6-mo 118.19%
1-year -61.22%
3-year -97.23%
5-year -99.62%
YTD 106.21%
2019 -76.85%
2018 -88.76%
2017 -47.79%
2016 -77.40%
2015 -69.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8001 seconds.